SRR23303743
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.520
- G2M_CHECKPOINT+0.350
- DNA_REPAIR+0.320
- PROTEIN_SECRETION+0.320
- MYC_TARGETS_V1+0.200
- HEME_METABOLISM+0.190
- OXIDATIVE_PHOSPHORYLATION+0.180
- MITOTIC_SPINDLE+0.160
- SPERMATOGENESIS+0.150
- FATTY_ACID_METABOLISM+0.130
Top 10 suppressed
- ALLOGRAFT_REJECTION-0.510
- TNFA_SIGNALING_VIA_NFKB-0.470
- INFLAMMATORY_RESPONSE-0.460
- IL6_JAK_STAT3_SIGNALING-0.420
- INTERFERON_GAMMA_RESPONSE-0.400
- KRAS_SIGNALING_UP-0.400
- INTERFERON_ALPHA_RESPONSE-0.380
- COAGULATION-0.350
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.340
- P53_PATHWAY-0.340
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 20040104.LumB | — | B | 0.924 |
| 2 | SRR12202425 | — | — | 0.918 |
| 3 | TCGA-GV-A3QI-01A-11R-A220-07 | — | — | 0.912 |
| 4 | MDT-AP-1258 | Med | Medulloblastoma | 0.909 |
| 5 | SRR1797245 | — | cohortSC | 0.904 |
| 6 | BS_4CP4T22V | Med | Medulloblastoma | 0.900 |
| 7 | R6 | — | — | 0.899 |
| 8 | SRR35579806 | — | B | 0.895 |
| 9 | MDT-AP-3021 | Med | Medulloblastoma | 0.895 |
| 10 | SRR1797277 | — | cohortSC | 0.894 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 18 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.520 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.350 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.320 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.320 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.200 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.190 | Temsirolimus | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.180 | Remibrutinib | — uncovered |
| MITOTIC_SPINDLE | 0.160 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.150 | Inavolisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.130 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.110 | Remibrutinib | — uncovered |
| GLYCOLYSIS | 0.110 | Inavolisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.060 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.060 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.030 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.020 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.010 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.010 | Idelalisib | — uncovered |